Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors
about
Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.Reverse Microemulsion-Based Synthesis of (Bis)phosphonate-Metal Materials with Controllable Physical Properties: An Example Using Zoledronic Acid-Calcium Complexes.Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.Nanomaterials as nanocarriers: a critical assessment why these are multi-chore vanquisher in breast cancer treatment.Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.
P2860
Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Zoledronic acid-encapsulating ...... unoresistance in breast tumors
@en
Zoledronic acid-encapsulating ...... noresistance in breast tumors.
@nl
type
label
Zoledronic acid-encapsulating ...... unoresistance in breast tumors
@en
Zoledronic acid-encapsulating ...... noresistance in breast tumors.
@nl
prefLabel
Zoledronic acid-encapsulating ...... unoresistance in breast tumors
@en
Zoledronic acid-encapsulating ...... noresistance in breast tumors.
@nl
P2093
P2860
P50
P356
P1433
P1476
Zoledronic acid-encapsulating ...... unoresistance in breast tumors
@en
P2093
Antonio Giordano
Chiara Riganti
Dario Ghigo
Elena Gazzano
Giuseppe De Rosa
Giuseppina Salzano
Stefania Porto
P2860
P304
20753-20772
P356
10.18632/ONCOTARGET.8012
P407
P577
2016-03-09T00:00:00Z